Peritoneal fluid treatment apparatus, package and method
    22.
    发明授权
    Peritoneal fluid treatment apparatus, package and method 失效
    腹膜液治疗仪,包装及方法

    公开(公告)号:US4128173A

    公开(公告)日:1978-12-05

    申请号:US722752

    申请日:1976-09-13

    摘要: The cannula of a conventional intravascular catheter is placed into the peritoneal cavity through a small shallow incision in antiseptically prepared skin. The stylet or trocar of the conventional catheter is removed; and a stainless steel elongated flexible guide is inserted through the catheter's cannula into the peritoneal cavity. The catheter's cannula is removed and a flexible elongated cannula inserted into the cavity over the guide and secured in place with a suture. Fluid operation means is connected to the elongated cannula by connector means to permit fluid treatment after removal of the guide. Apparatus to effect peritoneal fluid treatment are placed in sterile openable sealed packages for storage and transport.

    摘要翻译: 常规血管内导管的插管通过在防腐剂制备的皮肤中的小的浅切口放入腹腔。 去除常规导管的探针或套管针; 并且将不锈钢细长的柔性引导件穿过导管的插管插入腹膜腔中。 去除导管的套管,并将柔性细长插管插入引导件上的空腔中并用缝合线固定在适当位置。 流体操作装置通过连接器装置连接到细长插管,以在移除引导件之后允许流体处理。 用于进行腹膜液处理的装置放置在用于储存和运输的无菌可打开的密封包装中。

    Antipsychotic aminomethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-1,3-diaza-cyclopenta[a]naphthalene
    25.
    发明授权
    Antipsychotic aminomethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-1,3-diaza-cyclopenta[a]naphthalene 失效
    7,8-二氢-3H-6,9-二氧杂-1,3-二氮杂 - 环戊二烯并[a]萘的抗精神病药物氨基甲基衍生物

    公开(公告)号:US06803368B2

    公开(公告)日:2004-10-12

    申请号:US10128058

    申请日:2002-04-23

    IPC分类号: C07D49104

    CPC分类号: C07D491/04

    摘要: Compounds of the formula useful for treatment of disorders of the dopaminergic system, such as schizophrenia, schizoaffective disorder, bipolar disorder, Parkinson's disease, L-DOPA induced pychoses and dyskinesias, Tourette's syndrome and hyperprolactinemia and in the treatment of drug addiction such as the addiction to ethanol, nicotine or cocaine and related illnesses.

    摘要翻译: 用于治疗多巴胺能系统疾病如精神分裂症,分裂情感障碍,双相情感障碍,帕金森病,L-DOPA诱导的真菌和运动障碍,Tourette综合征和高催乳素血症以及治疗药物成瘾的成瘾的化合物,例如成瘾 乙醇,尼古丁或可卡因及相关疾病。

    4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists
    27.
    发明授权
    4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists 失效
    4-氨基 - (乙基氨基) - 氧吲哚多巴胺自身受体激动剂

    公开(公告)号:US06228880B1

    公开(公告)日:2001-05-08

    申请号:US09287675

    申请日:1999-04-07

    IPC分类号: A61K31404

    CPC分类号: C07D209/34

    摘要: Compounds having dopaminegic activity are provided, having the formula: wherein R1 and R2 are each, independently, hydrogen, C1-10 alkyl, or (CH2)mR4, wherein R4 is phenyl or naphthyl which may be substituted by one or two substituents selected from the group consisting of C1-6 alkyl, halogen, C1-6 alkoxide and trifluoromethyl and m is 1 to 5; and R3 is hydrogen or C1-6 alkyl; or pharmaceutically acceptable salts thereof.

    摘要翻译: 提供了具有多巴胺活性的化合物,其具有下式:其中R 1和R 2各自独立地为氢,C 1-10烷基或(CH 2)m R 4,其中R 4为苯基或萘基,其可以被一个或两个选自 由C 1-6烷基,卤素,C 1-6烷氧基和三氟甲基组成的组,m为1至5; 和R 3是氢或C 1-6烷基; 其药学上可接受的盐。

    Methods and apparatus for treating ischemic heart disease by providing transvenous myocardial perfusion
    28.
    发明授权
    Methods and apparatus for treating ischemic heart disease by providing transvenous myocardial perfusion 有权
    通过提供经静脉心肌灌注治疗缺血性心脏病的方法和装置

    公开(公告)号:US06186972B1

    公开(公告)日:2001-02-13

    申请号:US09208807

    申请日:1998-12-09

    IPC分类号: A61B1900

    摘要: Methods and apparatus for supplying retrograde perfusion of chronically ischemic myocardium by forming one or more transmural passageways between a cardiac chamber and the coronary venous vasculature. The placement, size and number of the passageways are selected, and portions of the venous vasculature or coronary ostium optionally partially or completely occluded, to maintain a parameter related to the pressure attained in the venous vasculature to a value less than a predetermined value.

    摘要翻译: 通过在心室和冠状静脉血管之间形成一个或多个透壁通道来供应慢性缺血心肌逆行灌注的方法和装置。 选择通道的位置,大小和数量,并且静脉血管或冠状口的部分可选地部分或完全闭塞,以将与静脉脉管系统中获得的压力相关的参数保持在小于预定值的值。

    Method for treatment of ischemic heart disease by providing transvenous
myocardial perfusion
    29.
    发明授权
    Method for treatment of ischemic heart disease by providing transvenous myocardial perfusion 失效
    通过提供经静脉心肌灌注治疗缺血性心脏病的方法

    公开(公告)号:US5655548A

    公开(公告)日:1997-08-12

    申请号:US714466

    申请日:1996-09-16

    摘要: Methods are provided for use in open surgical and transluminal methods for supplying long-term retrograde perfusion of the myocardium via a conduit disposed between the left ventricle and the coronary sinus. In a first method, an opening is formed between the left ventricle and the coronary sinus, and the coronary ostium is partially occluded using a stent that prevents the pressure in the coronary sinus from exceeding a predetermined value. In an alternative method, a first end of a conduit is inserted transeptally through the right atrium and obliquely into the posterior septal endocardium of the left ventricle via the posterior pyramidal space, while a second end of the conduit is inserted into the coronary sinus via the coronary ostium. A pressure-limiting valve is included in the conduit. In either method, the outlet from the left ventricle to the coronary sinus may include a one-way valve to prevent backflow from the coronary sinus into the left ventricle during cardiac diastole.

    摘要翻译: 提供了用于开放式外科和腔内方法的方法,用于通过设置在左心室和冠状窦之间的导管供应心肌的长期逆行灌注。 在第一种方法中,在左心室和冠状窦之间形成开口,并且使用防止冠状窦压力超过预定值的支架部分闭塞冠状口。 在替代方法中,导管的第一端通过右心房横切插入,并经由后金字塔形空间倾斜地插入左心室的后隔膜心内膜,而导管的第二端经由第二端插入冠状窦 冠状口。 管道中包括一个限压阀。 在任一方法中,从左心室到冠状窦的出口可以包括单向阀,以防止心脏舒张期期间从冠状窦逆流到左心室。

    (Thiophen-2-yl)-piperidin or tetrahydropyridin azabicyclocarboxamides
    30.
    发明授权
    (Thiophen-2-yl)-piperidin or tetrahydropyridin azabicyclocarboxamides 失效
    (噻吩-2-基) - 哌啶或四氢吡啶氮杂双环羧酰胺

    公开(公告)号:US5610164A

    公开(公告)日:1997-03-11

    申请号:US685132

    申请日:1996-07-24

    IPC分类号: C07D451/02 A61K31/435

    CPC分类号: C07D451/02

    摘要: This invention provides compounds having the structure ##STR1## wherein R is hydrogen, alkyl, alkenyl, alkynyl, --COR.sup.2, phenyl, or phenylalkyl; the dotted line represents an optional double bond;R.sup.1 is hydrogen, --OH, OR.sup.3, or is absent if the optional double bond is present;R.sup.2 and R.sup.3 are each, independently, alkyl, alkenyl, alkynyl, phenyl, or phenylalkyl;R.sup.4 is hydrogen, --OR.sup.5, alkyl, alkenyl, alkynyl, --COR.sup.5, --CO.sub.2 R.sup.5, --CONR.sup.5 R.sup.6, perhaloalkyl, halogen, phenyl, or phenylalkyl;R.sup.5 and R.sup.6 are each, independently, hydrogen, alkyl, alkenyl, alkynyl, phenyl, or phenylalkyl; andn=0-2or a pharmaceutically acceptable salt thereof that are useful as antipsychotic, antidepressant and anxiolytic agents useful in the treatment and relief of the symptoms of these disease states.

    摘要翻译: 本发明提供了具有结构“IMAGE”的化合物,其中R是氢,烷基,烯基,炔基,-COR 2,苯基或苯基烷基; 虚线表示可选的双键; R1是氢,-OH,OR3,如果存在任选的双键,则不存在; R2和R3各自独立地为烷基,烯基,炔基,苯基或苯基烷基; R 4是氢,-OR 5,烷基,烯基,炔基,-COR 5,-CO 2 R 5,-CONR 5 R 6,全卤代烷基,卤素,苯基或苯基烷基; R 5和R 6各自独立地为氢,烷基,烯基,炔基,苯基或苯基烷基; 和n = 0-2或其药学上可接受的盐,其可用作抗精神病药,抗抑郁药和抗焦虑剂,其用于治疗和缓解这些疾病状态。